Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01601704 · ClinicalTrials.gov registry record · Phase 3
Cardiovascular Outcomes Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects With Cardiovascular Risk Factors (The Light Study)
A Phase 3 study, sponsored by Orexigen Therapeutics.
- Terminated
- Registry status
- Phase 3
- Development phase
- 8,910
- Enrollment target
NCT01601704 is a Phase 3 study that was terminated before completion, run by Orexigen Therapeutics. The registered enrollment target is 8,910 participants.
The verdict
NCT01601704, a Phase 3 study, was terminated before completion, sponsored by Orexigen Therapeutics.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 8,910 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the effects of NB relative to placebo on major adverse cardiovascular events (MACE) such as cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke in overweight and obese subjects who are at a higher risk of having these events because they have diabetes and/or other cardiovascular risk factors.
Interventions
- DRUG PBO
- DRUG NB32
- BEHAVIORAL Weight Management Program
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8,910 participants |
| Start Date | 2012-06 |
| Est. Completion | 2015-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01601704
The ClinicalTrials.gov registry entry for NCT01601704 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 8,910 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Orexigen Therapeutics, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which PBO is the first listed.
NCT01601704 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01601704 about?
NCT01601704 is a clinical study titled "Cardiovascular Outcomes Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects With Cardiovascular Risk Factors (The Light Study)". The purpose of this study is to determine the effects of NB relative to placebo on major adverse cardiovascular events (MACE) such as cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke in overweight and obese subjects who are at a higher risk of having these events because t...
What is the current status of trial NCT01601704?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 8,910 participants. The study started on 2012-06. Estimated completion is 2015-08.
What interventions are being tested in trial NCT01601704?
The interventions under investigation include: PBO (DRUG), NB32 (DRUG), Weight Management Program (BEHAVIORAL).
Who is sponsoring clinical trial NCT01601704?
This trial is sponsored by Orexigen Therapeutics, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.